EHA 2025 | Improving outcomes for patients with BPDCN: alloSCT and maintenance therapy
Eric Deconinck, MD, PhD, CHU Besançon, Besançon, France, discusses strategies to improve outcomes for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr Deconinck highlights the importance of improving access to allogeneic stem cell transplantation (alloSCT) and the use of chemotherapy as maintenance therapy. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
What will be more important to cure this patient is to allow access to allotransplantation for the maximum number of patients, and if a patient cannot undergo allotransplantation, especially because this is an older population, as I already said, we have to build a chemotherapy such as maintenance therapy. And I think that this therapy will be based on CD123 molecules and also probably a combination of these molecules with proteasome inhibitors that are very efficient, BCL2 inhibitors that are also very efficient...
What will be more important to cure this patient is to allow access to allotransplantation for the maximum number of patients, and if a patient cannot undergo allotransplantation, especially because this is an older population, as I already said, we have to build a chemotherapy such as maintenance therapy. And I think that this therapy will be based on CD123 molecules and also probably a combination of these molecules with proteasome inhibitors that are very efficient, BCL2 inhibitors that are also very efficient. We know the use of these molecules in all patients, especially to treat acute myeloblastic leukemia, and I don’t think that with monotherapy we can cure this disease, so we have to work on these associations.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
